Eptinezumab-jjmr

Class: Calcitonin Gene-related Peptide (CGRP) Antagonists
- Anti-Calcitonin Gene-related Peptide Monoclonal Antibodies
- Anti-CGRP Monoclonal Antibodies
- Calcitonin Gene-related Peptide Antagonists
- CGRP Antagonists
Molecular Formula: C₆₃₅₂H₉₈₃₈N₁₆₉₄O₁₉₉₂S₄₆
CAS Number: 1644539-04-7
Brands: Vyepti

Medically reviewed by Drugs.com on Mar 31, 2022. Written by ASHP.

Introduction

Antimigraine agent; recombinant humanized IgG₁ monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand.

Uses for Eptinezumab-jjmr

Preventive Treatment of Migraine

Preventive treatment of migraine in adults.

Substantially reduces monthly migraine days in patients with episodic or chronic migraine when compared with placebo.

The American Headache Society (AHS) states that eptinezumab and other anti-CGRP monoclonal antibodies offer a number of advantages over some oral migraine preventive therapies, including no need for dosage escalation, rapid onset of therapeutic activity, minimal risk of adverse drug reactions, favorable overall tolerability profiles, and demonstrated efficacy after failure of prior preventive treatments or in combination with oral preventive treatments. However, the potential benefit of using newer therapies such as the anti-CGRP monoclonal antibodies over established therapies should be considered on an individual basis.

AHS has established a criteria for initiating treatment with anti-CGRP monoclonal antibodies based on a balance of cost-effective considerations and access to care; according to this criteria, use of anti-CGRP monoclonal antibodies may be appropriate when patients with migraine are unable to tolerate and/or have an inadequate response to an 8-week trial of at least 2 oral preventive therapies (e.g., topiramate, valproate, β-adrenergic blocking agents, tricyclic antidepressants, selective serotonin- and norepinephrine-reuptake inhibitors).

Eptinezumab-jjmr Dosage and Administration

Administration

IV Administration

Administer by IV infusion only. Do not administer by rapid IV injection (e.g., IV push or bolus). Do not mix eptinezumab with or administer simultaneously through the same IV line with other drugs.

Must be diluted prior to IV infusion.

Administer diluted solution through a separate IV line using a 0.2- or 0.22-µm inline or add-on sterile filter.

After completion of IV infusion, flush IV line with 20 mL of 0.9% sodium chloride injection.

Single-dose vials are intended for single use only and contain no preservatives; discard any unused portion in the vial.

Dilution

Prior to dilution, eptinezumab injection concentrate should be clear or slightly opalescent and colorless to brownish-yellow; do not use if solution appears cloudy or discolored or contains visible particles.

Must be diluted in polyvinyl chloride (PVC), polyethylene, or polyolefin infusion bags.

To prepare a 100-mg dose, withdraw 1 mL of injection concentrate from a single-dose vial (containing 100 mg/